To receive all the news in real time from NOXXON, please contact [email protected]
Berlin, Germany, April 14, 2022, 6:00 p.m. CEST – NOXXON Pharma NV (Euronext Growth Paris: ALNOX), a biotechnology company specializing in the development of improved cancer treatments targeting the tumor microenvironment (MET), today announces the convening of an extraordinary general meeting of shareholders of the company (EGM) on May 16, 2022, at 1.30 p.m. CEST, at the offices of Freshfields Bruckhaus Deringer LLP, Strawinskylaan 10, 1077 XZ in Amsterdam, The Netherlands.
This EGM is organized in order to approve the partial modification of the articles of association and the delegation of authority to cancel up to the total number of shares held by the company in its own capital in relation to the proposed share consolidation.